Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NFκB invivo

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 149-156

  Morrison, Martine ^a,b,c   van der Heijden, Roel ^b,c   Heeringa, Peter ^b   Kaijzel, Eric ^d   Verschuren, Lars ^a   Blomhoff, Rune ^e   Kooistra, Teake ^a   Kleemann, Robert ^a  

^a TNO   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Atherosclerosis; CRP; Epicatechin; Inflammation; NF B; Polyphenol

Indexed keywords

ATHEROSCLEROSIS; CRP; EPICATECHIN; INFLAMMATION; NFΚB; POLYPHENOL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CATECHIN; DIET, ATHEROGENIC; HUMANS; INFLAMMATION; MALE; MICE; MICE, TRANSGENIC; NF-KAPPA B;

EID: 84893842605     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.027     Document Type: Article

References (50)

1. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
2. Estruch R., Ros E., Salas-Salvado J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. NEngl J Med 2013, 368:1279-1290.
3. Nettleton J.A., Polak J.F., Tracy R., Burke G.L., Jacobs D.R. Dietary patterns and incident cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 2009, 90:647-654.
4. Siri-Tarino P.W., Sun Q., Hu F.B., Krauss R.M. Saturated fatty acids and risk of coronary heart disease: modulation by replacement nutrients. Curr Atheroscler Rep 2010, 12:384-390.
5. Chait A., Han C.Y., Oram J.F., Heinecke J.W. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. JLipid Res 2005, 46:389-403.
6. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011, l29:415-445.
7. Esmaillzadeh A., Kimiagar M., Mehrabi Y., Azadbakht L., Hu F.B., Willett W.C. Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr 2006, 84:1489-1497.
8. Holt E.M., Steffen L.M., Moran A., et al. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. JAm Diet Assoc 2009, 109:414-421.
9. Detopoulou P., Panagiotakos D.B., Chrysohoou C., et al. Dietary antioxidant capacity and concentration of adiponectin in apparently healthy adults: the ATTICA study. Eur J Clin Nutr 2010, 64:161-168.
10. van't Veer P., Jansen M.C., Klerk M., Kok F.J. Fruits and vegetables in the prevention of cancer and cardiovascular disease. Public Health Nutr 2000, 3:103-107.
11. Arts I.C., Hollman P.C. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005, 81:317S-325S.
12. Heiss C., Keen C.L., Kelm M. Flavanols and cardiovascular disease prevention. Eur Heart J 2010, 31:2583-2592.
13. Geleijnse J.M., Launer L.J., Van der Kuip D.A., Hofman A., Witteman J.C. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr 2002, 75:880-886.
14. Kuriyama S. The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. JNutr 2008, 138:1548S-1553S.
15. Buijsse B., Feskens E.J., Kok F.J., Kromhout D. Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med 2006, 166:411-417.
16. Larsson S.C., Virtamo J., Wolk A. Chocolate consumption and risk of stroke: a prospective cohort of men and meta-analysis. Neurology 2012, 79:1223-1229.
17. Ivey K.L., Lewis J.R., Prince R.L., Hodgson J.M. Tea and non-tea flavonol intakes in relation to atherosclerotic vascular disease mortality in older women. Br J Nutr 2013, 1-8.
18. Arranz S., Valderas-Martinez P., Chiva-Blanch G., et al. Cardioprotective effects of cocoa: clinical evidence from randomized clinical intervention trials in humans. Mol Nutr Food Res 2013, 57(6):936-947.
19. Hooper L., Kroon P.A., Rimm E.B., et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008, 88:38-50.
20. Knaze V., Zamora-Ros R., Lujan-Barroso L., et al. Intake estimation of total and individual flavan-3-ols, proanthocyanidins and theaflavins, their food sources and determinants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Nutr 2012, 108:1095-1108.
21. Arts I.C., Jacobs D.R., Harnack L.J., Gross M., Folsom A.R. Dietary catechins in relation to coronary heart disease death among postmenopausal women. Epidemiology 2001, 12:668-675.
22. Noll C., Lameth J., Paul J.L., Janel N. Effect of catechin/epicatechin dietary intake on endothelial dysfunction biomarkers and proinflammatory cytokines in aorta of hyperhomocysteinemic mice. Eur J Nutr 2013, 52:1243-1250.
23. Loke W.M., Proudfoot J.M., Hodgson J.M., et al. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arterioscler Thromb Vasc Biol 2010, 30:749-757.
24. Zadelaar S., Kleemann R., Verschuren L., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
25. Kleemann R., Verschuren L., van Erk M.J., et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 2007, 8:R200.
26. Kleemann R., Verschuren L., Morrison M., et al. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human invitro and invivo models. Atherosclerosis 2011, 218:44-52.
27. Carlsen H., Haugen F., Zadelaar S., et al. Diet-induced obesity increases NF-kappaB signaling in reporter mice. Genes Nutr 2009, 4:215-222.
28. Yakala G.K., Wielinga P.Y., Suarez M., et al. Effects of chocolate supplementation on metabolic and cardiovascular parameters in ApoE3L mice fed a high-cholesterol atherogenic diet. Mol Nutr Food Res 2013, 57(11):2039-2048.
29. Wielinga P.Y., Yakala G.K., Heeringa P., Kleemann R., Kooistra T. Beneficial effects of alternate dietary regimen on liver inflammation, atherosclerosis and renal activation. PLoS One 2011, 6:e18432.
30. Verschuren L., Radonjic M., Wielinga P.Y., et al. Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenet Genomics 2012, 22:837-845.
31. Manach C., Williamson G., Morand C., Scalbert A., Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005, 81:230S-242S.
32. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEngl J Med 2000, 342:836-843.
33. King V.L., Thompson J., Tannock L.R. Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011, 22:302-307.
34. O'Brien K.D., Chait A. Serum amyloid A: the "other" inflammatory protein. Curr Atheroscler Rep 2006, 8:62-68.
35. O'Brien K.D., McDonald T.O., Kunjathoor V., et al. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:785-790.
36. Lee H.Y., Kim M.K., Park K.S., et al. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun 2005, 330:989-998.
37. Dong Z., Wu T., Qin W., et al. Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med 2011, 17:1357-1364.
38. Ciliberto G., Arcone R., Wagner E.F., Ruther U. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J 1987, 6:4017-4022.
39. Kaptoge S., Di Angelantonio E., Lowe G., et al. for the Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
40. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. NEngl J Med 2005, 352:29-38.
41. Rotzius P., Thams S., Soehnlein O., et al. Distinct infiltration of neutrophils in lesion shoulders in ApoE-/- mice. Am J Pathol 2010, 177:493-500.
42. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012, 110:875-888.
43. Jensen L.E., Whitehead A.S. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998, 334(Pt 3):489-503.
44. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 2003, 101:545-551.
45. Chiba T., Kondo Y., Shinozaki S., et al. Aselective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. JAtheroscler Thromb 2006, 13:308-313.
46. de Vries-van der Weij J., Toet K., Zadelaar S., et al. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-kappaB activity and lowering of cholesterol. Atherosclerosis 2010, 213:241-246.
47. Gareus R., Kotsaki E., Xanthoulea S., et al. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab 2008, 8:372-383.
48. Mackenzie G.G., Carrasquedo F., Delfino J.M., Keen C.L., Fraga C.G., Oteiza P.I. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappaB activation at multiple steps in Jurkat T cells. FASEB J 2004, 18:167-169.
49. Al-Hanbali M., Ali D., Bustami M., et al. Epicatechin suppresses IL-6, IL-8 and enhances IL-10 production with NF-kappaB nuclear translocation in whole blood stimulated system. Neuro Endocrinol Lett 2009, 30:131-138.
50. Granado-Serrano A.B., Martin M.A., Haegeman G., Goya L., Bravo L., Ramos S. Epicatechin induces NF-kappaB, activator protein-1 (AP-1) and nuclear transcription factor erythroid 2p45-related factor-2 (Nrf2) via phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) and extracellular regulated kinase (ERK) signalling in HepG2 cells. Br J Nutr 2010, 103:168-179.